Loading...

SELLAS Life Sciences Group

DB:RXK2
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RXK2
DB
$21M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • SELLAS Life Sciences Group has significant price volatility in the past 3 months.
RXK2 Share Price and Events
7 Day Returns
-8.4%
DB:RXK2
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-79.6%
DB:RXK2
-10.6%
DE Biotechs
-6.2%
DE Market
RXK2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SELLAS Life Sciences Group (RXK2) -8.4% -22.6% -33.9% -79.6% - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • RXK2 underperformed the Biotechs industry which returned -10.6% over the past year.
  • RXK2 underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

RXK2 Value

 Is SELLAS Life Sciences Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for SELLAS Life Sciences Group. This is due to cash flow or dividend data being unavailable. The share price is €0.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SELLAS Life Sciences Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SELLAS Life Sciences Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RXK2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.15
NasdaqCM:SLS Share Price ** NasdaqCM (2019-04-23) in USD $0.92
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SELLAS Life Sciences Group.

DB:RXK2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SLS Share Price ÷ EPS (both in USD)

= 0.92 ÷ -3.15

-0.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SELLAS Life Sciences Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • SELLAS Life Sciences Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does SELLAS Life Sciences Group's expected growth come at a high price?
Raw Data
DB:RXK2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
18.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SELLAS Life Sciences Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SELLAS Life Sciences Group's assets?
Raw Data
DB:RXK2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.24
NasdaqCM:SLS Share Price * NasdaqCM (2019-04-23) in USD $0.92
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:RXK2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SLS Share Price ÷ Book Value per Share (both in USD)

= 0.92 ÷ 0.24

3.86x

* Primary Listing of SELLAS Life Sciences Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SELLAS Life Sciences Group is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess SELLAS Life Sciences Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. SELLAS Life Sciences Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RXK2 Future Performance

 How is SELLAS Life Sciences Group expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SELLAS Life Sciences Group expected to grow at an attractive rate?
  • SELLAS Life Sciences Group's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • SELLAS Life Sciences Group's earnings growth is expected to exceed the Germany market average.
  • Unable to compare SELLAS Life Sciences Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:RXK2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RXK2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 18.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RXK2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RXK2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 61 40 2
2022-12-31 0 12 -41 2
2021-12-31 0 -33 -35 2
2020-12-31 0 4 -29 2
2019-12-31 0 -19 -23 2
DB:RXK2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -30 -41
2018-09-30 -28 -37
2018-06-30 -16 -32
2018-03-31 -13 -30
2017-12-31 -11 -24
2017-09-30 -14 -21
2017-06-30 -16 -23
2017-03-31 -14 -20
2016-12-31 -12 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • SELLAS Life Sciences Group's earnings are expected to grow by 18.2% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if SELLAS Life Sciences Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RXK2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from SELLAS Life Sciences Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RXK2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.86 0.86 0.86 1.00
2022-12-31 -0.85 -0.54 -1.15 2.00
2021-12-31 -0.80 -0.52 -1.07 2.00
2020-12-31 -0.80 -0.63 -0.97 2.00
2019-12-31 -0.86 -0.83 -0.89 2.00
DB:RXK2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.15
2018-09-30 -4.99
2018-06-30 -6.63
2018-03-31 -8.48
2017-12-31 -10.44
2017-09-30 -10.88
2017-06-30 -316.07
2017-03-31 -15.62
2016-12-31 -18.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if SELLAS Life Sciences Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess SELLAS Life Sciences Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SELLAS Life Sciences Group has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RXK2 Past Performance

  How has SELLAS Life Sciences Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SELLAS Life Sciences Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SELLAS Life Sciences Group does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare SELLAS Life Sciences Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare SELLAS Life Sciences Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
SELLAS Life Sciences Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SELLAS Life Sciences Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RXK2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -41.25 13.27 8.77
2018-09-30 -37.39 10.17 6.10
2018-06-30 -32.41 12.05 5.45
2018-03-31 -29.79 10.98 5.69
2017-12-31 -24.43 9.39 6.07
2017-09-30 -21.35 11.05 9.14
2017-06-30 -23.27 9.53 12.13
2017-03-31 -19.82 6.28 11.94
2016-12-31 -17.68 4.59 11.40
2015-12-31 -8.23 2.92 4.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if SELLAS Life Sciences Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if SELLAS Life Sciences Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if SELLAS Life Sciences Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SELLAS Life Sciences Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SELLAS Life Sciences Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RXK2 Health

 How is SELLAS Life Sciences Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SELLAS Life Sciences Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SELLAS Life Sciences Group's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • SELLAS Life Sciences Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SELLAS Life Sciences Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • SELLAS Life Sciences Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SELLAS Life Sciences Group Company Filings, last reported 3 months ago.

DB:RXK2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.25 0.00 5.34
2018-09-30 18.46 0.08 9.97
2018-06-30 -2.48 7.78 1.35
2018-03-31 -1.32 9.68 3.47
2017-12-31 2.07 10.99 2.32
2017-09-30
2017-06-30 -4.36 5.98 4.77
2017-03-31 -5.00 7.37 5.96
2016-12-31 -5.00 7.37 5.96
2015-12-31 -12.26 10.93 1.40
  • SELLAS Life Sciences Group has no debt.
  • SELLAS Life Sciences Group currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • SELLAS Life Sciences Group has less than a year of cash runway based on current free cash flow.
  • SELLAS Life Sciences Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 38.3% each year.
X
Financial health checks
We assess SELLAS Life Sciences Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SELLAS Life Sciences Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RXK2 Dividends

 What is SELLAS Life Sciences Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SELLAS Life Sciences Group dividends.
If you bought €2,000 of SELLAS Life Sciences Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SELLAS Life Sciences Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SELLAS Life Sciences Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RXK2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RXK2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SELLAS Life Sciences Group has not reported any payouts.
  • Unable to verify if SELLAS Life Sciences Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SELLAS Life Sciences Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SELLAS Life Sciences Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SELLAS Life Sciences Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SELLAS Life Sciences Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SELLAS Life Sciences Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RXK2 Management

 What is the CEO of SELLAS Life Sciences Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Angelos Stergiou
TENURE AS CEO 7.3 years
CEO Bio

Dr. Angelos M. Stergiou, MD, ScD h.c., is the Founder, President and Chief Executive Officer of SELLAS Life Sciences Group AG (formerly, Sellas Inc.). Dr. Stergiou served as Vice President of Clinical Development & Medical Affairs at Anavex Life Sciences Corp. since February 2011. He served as Chairman of SELLAS Life Sciences Group AG from 2012 to September 30, 2016 and has been its Vice Chairman since July 2016. He has been a Director of SELLAS Life Sciences Group AG. since 2012. Dr. Stergiou has held international positions of increasing responsibility in the United States and Europe in pharma and biotechnology companies over the past 15 years including PAION AG, Accentia Biopharmaceuticals and BioVest International, Analytica International, as well as Clinical Research Organizations. Dr. Stergiou served as Vice President and Head of Drug Development at Accentia Biopharmaceuticals, Inc. from 2004 to 2008 and also served in the same capacity as well as Chief Medical Officer at its subsidiary Biovest International, Inc. during the same time. He has held specific roles ranging from Medical Director to Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Office with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC). He has led and overseen research endeavors in all Phases of clinical development across many indications, including CNS and Alzheimer's, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. Dr. Stergiou has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA and European health authorities in addition to Australia and Japan. He has extensive medical and clinical development expertise and has been involved in progressing Alzheimer's and numerous other clinical trials in prior roles. He also co-founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences (Genesis Research) prior to founding Sellas. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology. A prolific writer and respected editor, Dr. Stergiou has published papers in peer-reviewed literature and authored articles in journals in addition to being a reviewer/editor of peer-reviewed clinical journals. He has collaborated with the most internationally renowned academic institutions on clinical research endeavors including Beth Israel Deaconess Medical Center, MD Anderson Cancer Center, University of Pennsylvania, Cleveland Clinic, New York University, University of Heidelberg and the Mayo Clinic. Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College and a Fellow of the Royal Society of Medicine (UK – ID:00707077), He is an active member of the World Medical Association, the American Academy of Pharmaceutical Physicians and Investigators, the Association of Clinical Research Professionals and the International Society for Pharmacoeconomics and Outcomes Research. A frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and at post-secondary institutions including Columbia University, and numerous European universities. Dr. Stergiou holds an M.D. from the U.S. American Institute of Medicine and a Sc.D. h.c. from Kentucky Wesleyan College and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry. He completed elective clinical work in interventional cardiology at the General Hospital Hagen (Germany) and cardiac surgery at the University of Cologne. He is fluent in English, German and Greek.

CEO Compensation
  • Insufficient data for Angelos to compare compensation growth.
  • Insufficient data for Angelos to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the SELLAS Life Sciences Group management team in years:

2.5
Average Tenure
52
Average Age
  • The tenure for the SELLAS Life Sciences Group management team is about average.
Management Team

Angelos Stergiou

TITLE
Founder
TENURE
7.3 yrs

Marty Baum

TITLE
Chief Operating Officer
AGE
52
TENURE
2.5 yrs

John Burns

TITLE
VP of Finance
AGE
33
TENURE
0.3 yrs

Barbara Wood

TITLE
Executive VP
AGE
55
TENURE
1.1 yrs

Nick Sarlis

TITLE
Chief Medical Officer & Senior VP
TENURE
2.6 yrs

Christopher Shackleton

TITLE
Director of Clinical and Business Operations

Jörg Breitkopf

TITLE
Head of Clinical Operations

David Moser

TITLE
Vice President of Legal Affairs
Board of Directors Tenure

Average tenure and age of the SELLAS Life Sciences Group board of directors in years:

2.4
Average Tenure
62
Average Age
  • The average tenure for the SELLAS Life Sciences Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jane Wasman

TITLE
Chairman
AGE
62
TENURE
2.3 yrs

Angelos Stergiou

TITLE
Founder
TENURE
2.6 yrs

Jeff Weber

TITLE
Chairman of Scientific Advisory Board
TENURE
0.8 yrs

Larry Kwak

TITLE
Member of Scientific Advisory Board
TENURE
3.4 yrs

Jedd Wolchok

TITLE
Member of Scientific Advisory Board
TENURE
3.4 yrs

David Scheinberg

TITLE
Director
AGE
62

Sattva Neelapu

TITLE
Member of Scientific Advisory Board

Alex Eggermont

TITLE
Member of Scientific Advisory Board
TENURE
2.4 yrs

Javier Pinilla-Ibarz

TITLE
Member of Scientific Advisory Board
TENURE
2.4 yrs

Stephen Ghiglieri

TITLE
Director
AGE
56
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Jan 19 Sell Angelos Stergiou Individual 31. Dec 18 31. Dec 18 -23,277 €1.10 €-25,494
X
Management checks
We assess SELLAS Life Sciences Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SELLAS Life Sciences Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RXK2 News

Simply Wall St News

RXK2 Company Info

Description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has completed Phase II clinical trials for the treatment of acute myeloid leukemia and malignant pleural mesothelioma; is in Phase II clinical trials to treat multiple myeloma; and is in various development phases as a potential treatment for ovarian cancer. It also develops NeuVax that is in Phase II clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which have completed early stage trials in ovarian, endometrial, and breast cancers; and GALE-401, an anagrelide controlled release that has completed Phase II clinical trials in patients with essential thrombocythemia, as well as for the treatment of elevated platelets in patients with myeloproliferative neoplasms. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Details
Name: SELLAS Life Sciences Group, Inc.
RXK2
Exchange: DB
Founded:
$19,030,139
23,176,475
Website: http://www.sellaslifesciences.com
Address: SELLAS Life Sciences Group, Inc.
15 West 38th Street,
10th Floor,
New York,
New York, 10018,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SLS Common Shares Nasdaq Capital Market US USD 02. Jan 2018
DB RXK2 Common Shares Deutsche Boerse AG DE EUR 02. Jan 2018
Number of employees
Current staff
Staff numbers
8
SELLAS Life Sciences Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:27
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/03/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.